Technical Analysis for VIR - Vir Biotechnology, Inc.

Grade Last Price % Change Price Change
grade A 29.77 -13.13% -4.50
VIR closed down 13.13 percent on Wednesday, April 1, 2020, on 62 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical VIR trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Strong but Oversold Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Boomer Buy Setup Bullish Swing Setup -13.13%
Narrow Range Bar Range Contraction -13.13%
NR7 Range Contraction -13.13%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Biotechnology Coronavirus Therapeutic Products Astrazeneca Alnylam Pharmaceuticals Therapeutic Tuberculosis Pharmaceutical Companies Medimmune Rockefeller University Serious Infectious Diseases Treatment Of Hepatitis B

Is VIR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 75.0
52 Week Low 11.65
Average Volume 934,923
200-Day Moving Average 0.00
50-Day Moving Average 30.29
20-Day Moving Average 38.31
10-Day Moving Average 34.85
Average True Range 7.14
ADX 31.05
+DI 22.23
-DI 18.56
Chandelier Exit (Long, 3 ATRs ) 32.58
Chandelier Exit (Short, 3 ATRs ) 48.83
Upper Bollinger Band 50.76
Lower Bollinger Band 25.86
Percent B (%b) 0.16
BandWidth 64.99
MACD Line 0.24
MACD Signal Line 2.01
MACD Histogram -1.7732
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.23
Resistance 3 (R3) 37.97 36.23 35.98
Resistance 2 (R2) 36.23 34.33 35.86 35.57
Resistance 1 (R1) 33.00 33.16 32.13 32.26 35.15
Pivot Point 31.26 31.26 30.83 30.89 31.26
Support 1 (S1) 28.03 29.36 27.16 27.29 24.39
Support 2 (S2) 26.29 28.19 25.92 23.97
Support 3 (S3) 23.06 26.29 23.56
Support 4 (S4) 22.32